Dysregulation of the wnt pathway in solid tumors

Jenifer Prosperi, Hue H. Luu, Kathleen H. Goss

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Activation of the WNT signaling pathway has long been implicated in driving cancer pathogenesis from compelling evidence derived from complementary in vitro and animal studies. Moreover, there are extensive data supporting the nuclear localization of β-catenin, a surrogate marker frequently used as a read-out of WNT pathway activation, in addition to the overexpression of pathway activators and loss of pathway inhibitors in human cancers. Despite being most often linked with colorectal cancer, WNT pathway activation has now been associated with virtually every type of solid cancer that occurs in humans, although the frequency can vary dramatically among tumor subtypes and specific pathway components. These findings have significant implications regarding the mechanisms by which pathway activation might drive tumor development in specific tumor subtypes as well as the potential utility and impact of targeting this pathway therapeutically. In this chapter, we will summarize, both by tumor type and pathway components, the expansive evidence suggesting that the pathway is dysregulated in nearly half of all the most common types of human malignancies.

Original languageEnglish (US)
Title of host publicationTargeting the Wnt Pathway in Cancer
PublisherSpringer New York
Pages81-128
Number of pages48
ISBN (Print)9781441980229
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Wnt Signaling Pathway
Neoplasms
Catenins
Colorectal Neoplasms
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prosperi, J., Luu, H. H., & Goss, K. H. (2011). Dysregulation of the wnt pathway in solid tumors. In Targeting the Wnt Pathway in Cancer (pp. 81-128). Springer New York. https://doi.org/10.1007/978-1-4419-8023-6_5

Dysregulation of the wnt pathway in solid tumors. / Prosperi, Jenifer; Luu, Hue H.; Goss, Kathleen H.

Targeting the Wnt Pathway in Cancer. Springer New York, 2011. p. 81-128.

Research output: Chapter in Book/Report/Conference proceedingChapter

Prosperi, J, Luu, HH & Goss, KH 2011, Dysregulation of the wnt pathway in solid tumors. in Targeting the Wnt Pathway in Cancer. Springer New York, pp. 81-128. https://doi.org/10.1007/978-1-4419-8023-6_5
Prosperi J, Luu HH, Goss KH. Dysregulation of the wnt pathway in solid tumors. In Targeting the Wnt Pathway in Cancer. Springer New York. 2011. p. 81-128 https://doi.org/10.1007/978-1-4419-8023-6_5
Prosperi, Jenifer ; Luu, Hue H. ; Goss, Kathleen H. / Dysregulation of the wnt pathway in solid tumors. Targeting the Wnt Pathway in Cancer. Springer New York, 2011. pp. 81-128
@inbook{77b32cc45fa64f39b92411d8bd4a828f,
title = "Dysregulation of the wnt pathway in solid tumors",
abstract = "Activation of the WNT signaling pathway has long been implicated in driving cancer pathogenesis from compelling evidence derived from complementary in vitro and animal studies. Moreover, there are extensive data supporting the nuclear localization of β-catenin, a surrogate marker frequently used as a read-out of WNT pathway activation, in addition to the overexpression of pathway activators and loss of pathway inhibitors in human cancers. Despite being most often linked with colorectal cancer, WNT pathway activation has now been associated with virtually every type of solid cancer that occurs in humans, although the frequency can vary dramatically among tumor subtypes and specific pathway components. These findings have significant implications regarding the mechanisms by which pathway activation might drive tumor development in specific tumor subtypes as well as the potential utility and impact of targeting this pathway therapeutically. In this chapter, we will summarize, both by tumor type and pathway components, the expansive evidence suggesting that the pathway is dysregulated in nearly half of all the most common types of human malignancies.",
author = "Jenifer Prosperi and Luu, {Hue H.} and Goss, {Kathleen H.}",
year = "2011",
doi = "10.1007/978-1-4419-8023-6_5",
language = "English (US)",
isbn = "9781441980229",
pages = "81--128",
booktitle = "Targeting the Wnt Pathway in Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Dysregulation of the wnt pathway in solid tumors

AU - Prosperi, Jenifer

AU - Luu, Hue H.

AU - Goss, Kathleen H.

PY - 2011

Y1 - 2011

N2 - Activation of the WNT signaling pathway has long been implicated in driving cancer pathogenesis from compelling evidence derived from complementary in vitro and animal studies. Moreover, there are extensive data supporting the nuclear localization of β-catenin, a surrogate marker frequently used as a read-out of WNT pathway activation, in addition to the overexpression of pathway activators and loss of pathway inhibitors in human cancers. Despite being most often linked with colorectal cancer, WNT pathway activation has now been associated with virtually every type of solid cancer that occurs in humans, although the frequency can vary dramatically among tumor subtypes and specific pathway components. These findings have significant implications regarding the mechanisms by which pathway activation might drive tumor development in specific tumor subtypes as well as the potential utility and impact of targeting this pathway therapeutically. In this chapter, we will summarize, both by tumor type and pathway components, the expansive evidence suggesting that the pathway is dysregulated in nearly half of all the most common types of human malignancies.

AB - Activation of the WNT signaling pathway has long been implicated in driving cancer pathogenesis from compelling evidence derived from complementary in vitro and animal studies. Moreover, there are extensive data supporting the nuclear localization of β-catenin, a surrogate marker frequently used as a read-out of WNT pathway activation, in addition to the overexpression of pathway activators and loss of pathway inhibitors in human cancers. Despite being most often linked with colorectal cancer, WNT pathway activation has now been associated with virtually every type of solid cancer that occurs in humans, although the frequency can vary dramatically among tumor subtypes and specific pathway components. These findings have significant implications regarding the mechanisms by which pathway activation might drive tumor development in specific tumor subtypes as well as the potential utility and impact of targeting this pathway therapeutically. In this chapter, we will summarize, both by tumor type and pathway components, the expansive evidence suggesting that the pathway is dysregulated in nearly half of all the most common types of human malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84873059623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873059623&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-8023-6_5

DO - 10.1007/978-1-4419-8023-6_5

M3 - Chapter

AN - SCOPUS:84873059623

SN - 9781441980229

SP - 81

EP - 128

BT - Targeting the Wnt Pathway in Cancer

PB - Springer New York

ER -